High Growth Tech Stocks In Germany Including adesso And 2 More

In This Article:

As global markets react to the recent Federal Reserve rate cut, European indices have shown mixed results, with Germany's DAX index posting a modest gain. In this dynamic environment, high-growth tech stocks in Germany present intriguing opportunities for investors looking to capitalize on innovation and market resilience. Identifying strong candidates involves assessing their growth potential and how well they navigate current economic conditions.

Top 10 High Growth Tech Companies In Germany

Name

Revenue Growth

Earnings Growth

Growth Rating

Formycon

31.78%

30.52%

★★★★★☆

Ströer SE KGaA

7.39%

29.88%

★★★★★☆

Stemmer Imaging

13.34%

23.20%

★★★★★☆

Exasol

14.66%

117.10%

★★★★★☆

ParTec

41.16%

63.31%

★★★★★★

Northern Data

32.53%

68.17%

★★★★★☆

cyan

27.51%

67.46%

★★★★★☆

medondo holding

35.61%

82.66%

★★★★★☆

Rubean

55.25%

67.67%

★★★★★☆

GK Software

8.70%

33.04%

★★★★☆☆

Click here to see the full list of 42 stocks from our German High Growth Tech and AI Stocks screener.

Let's explore several standout options from the results in the screener.

adesso

Simply Wall St Growth Rating: ★★★★☆☆

Overview: adesso SE, along with its subsidiaries, offers IT services across Germany, Austria, Switzerland, and internationally with a market cap of €443.38 million.

Operations: The company generates revenue primarily from IT services (€1385.63 million) and IT solutions (€128.12 million), with some offsets due to consolidation (-€267.88 million) and reconciliation (-€20.92 million).

Despite a challenging half-year with sales rising to €633.47 million, adesso SE faced a deepening net loss of €9.86 million, reflecting intensified competitive pressures and higher operational costs in the tech sector. The firm's R&D expenses are critical for its rebound, marked by an aggressive strategy to innovate within the digital transformation space. Notably, adesso's revenue growth forecast at 11.7% annually outpaces the German market average of 5.5%, indicating potential for recovery and expansion in its software solutions segment. With earnings expected to surge by 46.45% per year, the company is poised for a significant turnaround, banking on its enhanced product offerings and strategic market positioning to drive future profitability.

XTRA:ADN1 Revenue and Expenses Breakdown as at Sep 2024
XTRA:ADN1 Revenue and Expenses Breakdown as at Sep 2024

Formycon

Simply Wall St Growth Rating: ★★★★★☆

Overview: Formycon AG, a biotechnology company, develops biosimilar drugs in Germany and Switzerland with a market cap of €930.52 million.

Operations: The company generates revenue primarily from its Drug Delivery Systems segment, which accounted for €60.80 million.